Table 3.

Accelerated Phase Features at Baseline and Evolution During Follow-Up

Accelerated Phase Feature	Patients		Median Survival Time (months)
	No.	%
Present at diagnosis (baseline)
Blood or marrow blasts ≥ 10%	14	4	12
Platelets < 50 × 109/L	50	14	14
Abnormal Chromosome 17	2	< 1	< 6
Multiple features*	11	3	6
Evolution of accelerated feature during follow-up
Blood or marrow blasts ≥ 10%	26		12
Platelets < 50 × 109/L	20		15
Abnormal chromosome 17	6		6

^*The baseline category multiple features included six patients with abnormal chromosome 17 and thrombocytopenia, four patients with increased blasts and thrombocytopenia, and one patient with all three features.